IPMN is a common subtype of precancerous lesions of the pancreas that can advance to invasive carcinoma if left untreated. Although patients with IPMN associated with invasive cancer face better prognosis than those with conventional pancreatic ductal adenocarcinoma, the 5-year survival is poor and surgical resection remains the most effective treatment option for the patients. Currently there is no effective way of monitoring the malignant transformation of IPMN to invasive cancer and there is no established consensus in making the surgical decision. Considering the high-risk natures of malignant transformation and surgical resections, it is therefore crucial to establish a protocol balancing the risks for both. Here we report the potential uses of PTEN expression as a prognostic/diagnostic marker for IPMN patients. In addition, the extensive dysregulation of the PI3K signaling pathway in IPMN suggest that targeted therapies to this pathway may benefit patients with IPMN.
INTRODUCTION
Pancreatic adenocarcinoma is a malignancy of extremely poor prognosis with high mortality and short survival. Methods for its early detection and effective treatments, which will require an understanding of the underlying mechanisms of its development, are urgently needed.
Pancreatic adenocarcinoma is thought to develop from precancerous lesions such as PanIN (pancreatic intraepithelial neoplasia), IPMN, and MCN (mucinous cystic neoplasm) (1) . IPMN is the most common cystic precancerous lesion of the pancreas, representing ~20% of surgically resected cystic lesions of the pancreas (2, 3) . The prognosis for non-invasive IPMN is excellent and detection and surgical intervention at the preinvasive stage is curative (4, 5) . The prognosis is poor for tumors with associated invasive adenocarcinoma, but still more favorable than for conventional pancreatic ductal adenocarcinoma (PDAC) arising from PanIN lesions (6) . The specific mutations leading to the development of various histological grades of IPMN have been partially characterized in previous studies (11) (12) (13) . Reported genetic alterations identified in IPMN include mutations in KRAS (11, 14, 15) , GNAS (16, 17) , PIK3CA (12) and BRAF (11) . Other changes include the loss of expression of STK11/LKB1 (18) (19) (20) and overexpression of TP53 and ERBB2 proteins in the IPMNs (15) , and allelic loss of PTEN in the pancreatic cyst fluid DNA of IPMN patients (21) function by mutation or deletion, leading to the accumulation of the PI3K product phosphatidylinositol 3-phosphate (PIP 3 ). The accumulation of PIP 3 activates a signaling cascade starting with the phosphorylation (activation) of the protein serine-threonine kinase AKT by 3-phosphoinositide dependent protein kinase-1 (PDK1/PDPK1). PDK1 is considered a "master kinase" which phosphorylates and is responsible for the activation of all ACG family members, many of them related to cell proliferation, survival or the inhibition of apoptosis, including AKT1, 2 and 3 (23, 24).
Germline mutations in the PTEN gene can cause Cowden syndrome with cancer predisposition, and it is commonly sporadically mutated in prostate cancer, endometrial cancer and glioblastoma among others (25, 26 (12) . Consistent to our finding, Lubezky et al. recently described the detection of H1047R hot-spot mutation in two of 27 IPMN cases, one of which was a low-grade IPMN (39) .
Rare or absent activating somatic mutations in the AKT1 gene have also been recently described (40) (41) (42) . The E17K mutation in the pleckstrin homology domain of the AKT1 gene can result in PI3K-independent membrane recruitment of Akt, recapitulating the effects of the AKT8 murine leukemia retrovirus GAG-AKT fusion protein. E17K-AKT1 exhibits transforming activity in vitro and in vivo, albeit at lower level than the myristoylated Akt (40, 41) . To-date, the mutational status of the AKT1 gene has not been evaluated in IPMN.
The aim of this study was to evaluate the status of the PI3K pathway and its association with clinicopathological variables in 36 IPMN at the molecular level by analyzing the hot-spot mutations in the AKT1 and PIK3CA genes, the LOH status at the PTEN gene locus, and expression levels of PTEN and PDK1. This pathway contains many putative therapeutic targets; knowing the prevalence of alterations in this pathway may be useful to determine its potential diagnostic and therapeutic applications to IPMN patients.
Research. 
MATERIALS AND METHODS

Patients and tissue samples
Thirty-six formalin fixed paraffin embedded IPMN were obtained from the archival tissue collection at the CUMC. The 36 cases were chosen based on their histological typing for a balanced presentation of IPMN-1-3 for a tissue microarray. We chose to Table 1 . Patients with pancreatic neoplasms were recruited to our institutional prospective longitudinal outcomes study. Patients being followed for premalignant cystic neoplasms were evaluated with cross sectional imaging and / or endoscopic ultrasound every 6 to 12 months depending on patient specific demographics. 
Mutational Analysis of the PIK3CA gene
Mutations in exons 9 and 20 of the PIK3CA gene were analyzed by direct genomic sequencing methods and confirmed by our previously described mutantenriched sequencing method (44) . Polymerase chain reaction (PCR) amplification of genomic DNA (40 ng each) and direct sequencing of the PCR products were performed using the same primers and conditions as previously described (44) . All PCR fragments were purified using ExoSAP-IT kit (Affymetrix, Santa Clara, CA) and sequencing was performed with ABI Prism 3730xl DNA analyzers by Genewiz, Inc (South Plainfield, NJ) using the PCR primers (44) . Any alteration detected was further verified by sequencing of a second PCR product derived independently from the original DNA template.
Conventional direct genomic sequencing of the AKT1 gene
The point mutation G > A at nucleotide 49 of the AKT1 gene (E17K) was first examined by direct genomic sequencing. Genomic DNA was amplified with primers designed to amplify exclusively the hot-spot (AKT1-F 5' -ACATCTGTCCTGGCACAC -3': AKT1-R 5' -GCCAGTGCTTGTTGCTTG -3') (40) . All PCR fragments were purified using Invitrogen PureLink TM PCR purification kit (Life Technologies, Carlsbad, CA) and sequencing was carried out with ABI 3730x/DNA analyzers by Genewiz, Inc.
Mutant-enriched sequencing for detecting AKT1 mutation E17K
Based on the same principles that we have employed to design the mutantenriched sequencing method for PIK3CA (44), here we developed a sensitive mutantenriched sequencing method specific for the E17K hot-spot mutation of the AKT1 gene (Fig. 1A) . A mismatched primer was designed to create a unique restriction enzyme site for EcoRI in the AKT1 exon 2 region in the first round of PCR. The mismatched primer AKT1ME-R (5' -GGCCGCCAGGTCTTGATGAATT -3') was used as the reverse primer for both rounds of PCR. The forward primers for the first and second PCR were respectively AKT1ME-F1 (5' -GGCTGTGCAGACTGGCCCAG -3') and AKT1ME-F2 (5' -ACACAGCTCGGGGTGGCTCT -3'). EcoRI digestion was performed at 37°C overnight. The forward PCR primer AKT1ME-F2 was also used as the DNA sequencing primer (Fig. 1A) . Any alteration detected was further verified at least twice by repeating the process starting with a second PCR product derived independently from the original DNA template. To develop the method, a 583bp product containing the E17K hot-spot mutation was amplified using a known mutant DNA sample as a template, using primers AKT1G49AFwd 5'-ACATCTGTCCTGGCACAC -3' and AKT1G49ARvs 5'-GCCAGTGCTTGTTGCTTG -3'. The PCR product was subcloned into a pcDNA Mutant and wild-type colonies were sequenced and selected. To determine the approximate sensitivity of our assay, we made serial dilutions of the mutant plasmid with the wild-type plasmid. When the ratio of the mutant to wild-type DNA copies reached 1:100, the mutant-enriched sequencing result still contained a recognizable mutant peak.
However, conventional direct genomic sequencing, the mutant peak disappeared when the ratio of mutant and wild-type DNA was lower than 1:10. This indicated that the mutant-enriched sequencing method was at least 10 times more sensitive than the conventional sequencing method. from the Ensembl database. SNPs reported to have high heterozygosity indices were chosen. Twenty-seven SNPs with high heterozygosity indices were checked for the presence of restriction endonuclease site using the SNP cutter program (available at http://bioinfo.bsd.uchicago.edu/SNP_cutter.htm.) as described previously (45) . We identified eight SNPs; each harbors a unique restriction site. Primers were designed for each SNP to generate a PCR product of 200-350 bp. Of the eight SNPs, seven yielded bands of distinguishable unequal sizes upon restriction digestion that were detectable on an agarose gel. The selected seven SNPs were then employed for the LOH analyses.
Digestion of the PCR products was carried out with appropriate restriction enzymes (New England Biolabs Inc. Ipswich, MA) and resolved on 1% agarose gel. One SNP (rs34421660) was described as a deletion/insertion with a 32bp difference between both alleles, allowing the analysis without restriction enzyme digestion. All the primers were ordered from Sigma-Aldrich (St. Louis, MO).
For LOH analyses, only those sample pairs in which non-neoplastic DNA showed a heterozygous pattern were considered informative. Non-neoplastic DNA with a homozygous pattern was considered not informative for that SNP marker and excluded from the study. Allelic loss was recorded if the intensity of the signal from one allele was reduced at least 50% in the tumor DNA when compared to that in the non-neoplastic DNA for a given SNP marker on visual inspection by 2 independent observers (46) (A.T.T. and D.G.C.). PTEN oligonucleotides, locus and restriction enzymes are listed in 
Statistical analysis
regression models were conducted to calculate the odds ratio and 95% confidence interval for the association between PTEN expression and the presence of invasive carcinoma; the model adjusted for PDK1 expression. Survival curves were calculated using Kaplan-Meier product-limit estimate. Differences between survival times were analyzed by the log-rank method. Multivariable Cox proportional hazards models were used to calculate hazard ratios and 95% confidence interval of the association between risk factors and survival.
We included variables in our multivariable model that were statistically significant in the univariate analysis; these variables include: PTEN expression, presence of invasive carcinoma and age). All tests were two sided. P values ≤ 0.05 were considered statistically significant. All statistical analyses were performed using SPSS statistical software version 17.0 (SPSS Inc. Chicago, IL, USA).
RESULTS
Mutations in PIK3CA and AKT1
IPMN were examined for the presence of the hot-spot mutations in the AKT1 and PIK3CA genes. We used both direct genomic sequencing and mutant-enriched sequencing methods on the DNA samples extracted from 36 microdissected IPMN specimens. One patient with borderline IPMN (moderate dysplasia) harbored the H1047R (A3140G) hot-spot mutation of the PIK3CA gene in the IPMN (data not shown). The E17K (A49G) AKT1 gene mutation was detected in three IPMN; two of the three were intestinal-type and one was gastric-type IPMN. While the PIK3CA mutation was detected by direct genomic sequencing, the three AKT1 mutations were identified only when the newly developed mutant-enriched sequencing method was employed (Fig.1) . Using Taqman ® Mutation Detection Assay for AKT1 E17K, we confirmed the presence of the AKT1 E17K mutation in two of the three positive cases. The mutations were somatic because they were not observed in the corresponding normal tissues of the same patients.
Analysis of AKT1 and PIK3CA gene amplification in IPMN
The AKT1 and PIK3CA gene loci were investigated for potential amplification in the 36 IPMN specimens by Q-PCR. Gene amplification of the AKT1 locus was detected in one IPMC specimen (2.8%). PIK3CA gene amplification was detected in seven 
Analysis of PTEN LOH
Of the 36 cases, 28 (77.8%) showed heterozygosity at the PTEN locus by SNP-PCR-RFLP, and eight were not informative (as defined in the Material and Methods) for all the seven SNPs analyzed. Of the 28 heterozygous cases, 10 displayed LOH (10/28, 35.7%) ( Table 1) .
PTEN, PDK1 and Ki67 protein expression in IPMN
The protein expression levels of PTEN, PDK1 and Ki67 were studied by Table 3 ). It was also observed that PDK1 was more commonly overexpressed in IPMC than IPMN adenoma and borderline tumor (Fisher's exact, p = 0.034), showing an increasing trend with IPMN progression: Adenoma (0/2; 0%); Borderline (3/9; 33.3%); In situ (17/25; 68%). All the cases with PDAC associated, (7/7; 100%) showed strong PDK1 expression. Moreover, PDK1 overexpression showed a linear correlation with the maximum cyst diameter detected (Chi-square, p = 0.044).
A striking difference in survival was observed between patients with normal expression of PTEN and those with reduced or absent PTEN expression; the latter group experienced shortened disease-specific survival (Median survival time: PTEN normal= 60.6 months, PTEN low = 48.9 months; log-rank test, p = 0.014, Fig. 3) . As expected IPMN patients with an invasive carcinoma had poorer survival than those without invasive carcinoma; a 12 fold increase risk of mortality was observed in multivariable models adjusting for PTEN expression and presence of invasive carcinoma (hazard ratio = 11.9, 95% CI = 1.7-83.5, p = 0.012); addition of age to the model, did not affect the result. This result may indicate that the association of PTEN expression with patient survival was only due to the presence of invasive carcinoma (Fisher's exact, p = 0.018).
When we examined the factors associated with the presence of invasive carcinoma, absent or weak PTEN expression was associated with a 8-fold increase in the odds controlling for PDK1 expression (odd ratio = 8.3, 95% CI = 1.034-67.142, p = 0.046).
However, these results are based on a small sample size. We identified the H1047R mutation of PIK3CA in one (2.7%) of the 36 IPMN.
We also detected the E17K AKT1 gene mutation in three (8.3%) of the 36 IPMN cases.
The H1047R mutation of PIK3CA is known to affect the functionally important kinase domain of the protein, conferring an increased lipid kinase activity, which can lead to the activation of PI3K signaling pathway in the absence of growth factors. The mutation has been shown to be sufficient to induce oncogenic cell transformation of chicken embryo fibroblasts (CEFs) and NIH3T3 cells (36, 37, 47) . It has also been described that p110α mutants induce in vivo angiogenesis and malignant cell growth in chorioallantoic membrane of chick embryo and cause hemangiosarcomas in young chickens (36).
We have previously reported PIK3CA gene mutations in 11% of IPMN, suggesting that the PIK3CA gene and its pathway may have a role in IPMN but not PanIN/PDA tumorigenesis (12) . In our previous study, PIK3CA gene mutations were detected in three high-grade IPMN, and one IPMN, borderline, with the caveat that the majority of the cases examined had high-grade dysplasia. One of the four mutations detected in the previous study was H1047R in a IPMC with invasion, the other three were not hot-spot mutations (12) . In the current study more IPMN with low-grade and borderline dysplasia were included and the hot-spot mutation H1047R was detected in an IPMN, borderline. The mutation frequency is slightly lower in the current study probably due to the facts that more low-grade cases were included and only hot-spot mutation sites were examined. Nevertheless, a number of recent studies encompassing different histological grades of IPMN are in agreement with our findings, supporting an important role for PIK3CA in IPMN (12, 39, 48 ). There is one exception in which PIK3CA mutations were not detected in IPMN but were identified in intraductal tubulopapillary neoplasms of the pancreas (ITNP), a rare variant of intraductal neoplasm of the pancreas recently recognized as a new class of pancreatic tumor (13) . Consistent expression of MUC5A among our samples definitively confirmed them as IPMN and ruled out ITNP (data not shown) (9) .
The mutational status of AKT1 gene has not been examined before in IPMN. Here we show that by using a novel mutant-enriched method, we were able to detect the E17K mutation in three (8.3%) of the 36 IPMN cases; two of those were IPMC associated with invasive components. The detection of the AKT1 E17K mutation in IPMN but not PDA further signified the unique importance of the PI3K signaling pathway in IPMN progression. While presence of false positive mutations could be possible due to a lowquantity DNA extracted from the tumors and/or a potential non-template extension of the AKT1ME-R primer used in the mutant-enriched assay, the absence of a mutant peak on any of the paired normal samples examined suggests that this a rather infrequent event.
Furthermore, each positive sample was verified from an independent PCR of the original genomic DNA at least two more times. To further rule out false positivity, new DNA from the same potential positive cases was extracted, the presence of AKT1 E17K mutations was then analyzed using the AKT1 E17K Taqman ® Mutation Detection Assay.
By using this method, we were able to confirm two of the three potential positive cases. The apparent discrepancy could be due to a number of reasons: (1) different mutant to wild-type ratio between the different DNA samples from the same patients; (2) different sensitivity of the two methods applied; or (3) lack of calibration ΔCt value for the AKT1_33765_mu assay, could lead to a smaller detection ΔCt cutoff calculated with our samples, which could limit the detection of mutant allele. 
PTEN. PIK3CA was amplified in 19.4% of the IPMN analyzed, while AKT1 was amplified in only one IPMN associated with invasive carcinoma. These events did not correlate with the clinical variables.
Although we found PDK1 to be frequently overexpressed in our IPMN samples (20/36 or 55.6%), this overexpression was not associated with patient survival. However, PDK1 expression was significantly higher in intestinal and pancreatic-type IPMN vs. Within this manuscript, we examined a large number of associations, and we observed a limited number of significant associations. Thus, due to the issues of multiple comparisons, we are cautious in our interpretations of the results; some of the statistically significant associations we observed may be explained by chance. Using a conservative approach of Bonferroni correction, we would require a p-value of <0.003 to achieve statistical significance. Based on this p-value, none of our results would be statistically significant, and may all be a result of chance. However, these statistically significant findings are supported by well-defined biologic rationale (e.g. PDK1 overexpression and PTEN loss in IPMN progression are logical) (26, 31) . Thus, these results require replication in larger studies. 
